Nikolai Lorenzen
Overview
Explore the profile of Nikolai Lorenzen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
691
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ostergaard H, Lund J, Greisen P, Kjellev S, Henriksen A, Lorenzen N, et al.
Blood
. 2021 Jun;
138(14):1258-1268.
PMID: 34077951
Hemophilia A is a bleeding disorder resulting from deficient factor VIII (FVIII), which normally functions as a cofactor to activated factor IX (FIXa) that facilitates activation of factor X (FX)....
12.
Wahlund P, Lorenzen N, Rischel C
J Pharm Sci
. 2021 Feb;
110(6):2336-2339.
PMID: 33640337
We describe a new method for screening protein-protein interaction of biopharmaceutical molecules at dilute concentrations to predict development issues at high concentration. The method is based on Asymmetrical Flow Field-Flow...
13.
Narayanan H, Dingfelder F, Butte A, Lorenzen N, Sokolov M, Arosio P
Trends Pharmacol Sci
. 2021 Jan;
42(3):151-165.
PMID: 33500170
Successful biologics must satisfy multiple properties including activity and particular physicochemical features that are globally defined as developability. These multiple properties must be simultaneously optimized in a very broad design...
14.
Kopp M, Wolf Perez A, Zucca M, Capasso Palmiero U, Friedrichsen B, Lorenzen N, et al.
MAbs
. 2020 Sep;
12(1):1815995.
PMID: 32954930
High physical stability is required for the development of monoclonal antibodies (mAbs) into successful therapeutic products. Developability assays are used to predict physical stability issues such as high viscosity and...
15.
Sakhnini L, Greisen P, Wiberg C, Bozoky Z, Lund S, Wolf Perez A, et al.
Biochemistry
. 2019 May;
58(24):2750-2759.
PMID: 31117388
Aggregation can be a major challenge in the development of antibody-based pharmaceuticals as it can compromise the quality of the product during bioprocessing, formulation, and drug administration. To avoid aggregation,...
16.
Wolf Perez A, Sormanni P, Andersen J, Sakhnini L, Rodriguez-Leon I, Rose Bjelke J, et al.
MAbs
. 2018 Dec;
11(2):388-400.
PMID: 30523762
Despite major advances in antibody discovery technologies, the successful development of monoclonal antibodies (mAbs) into effective therapeutic and diagnostic agents can often be impeded by developability liabilities, such as poor...
17.
Kurnik M, Sahin C, Andersen C, Lorenzen N, Giehm L, Mohammad-Beigi H, et al.
Cell Chem Biol
. 2018 Sep;
25(11):1389-1402.e9.
PMID: 30197194
α-Synuclein (αSN) aggregation is central to the etiology of Parkinson's disease (PD). Large-scale screening of compounds to identify aggregation inhibitors is challenged by stochastic αSN aggregation and difficulties in detecting...
18.
Sahin C, Lorenzen N, Lemminger L, Christiansen G, Moller I, Vesterager L, et al.
Biophys Chem
. 2016 Nov;
220:34-41.
PMID: 27863716
The 140-residue natively disordered protein α-synuclein (aSN) is a central component in the development of a family of neurodegenerative diseases termed synucleinopathies. This is attributed to its ability to form...
19.
Jarvela T, Lam H, Helwig M, Lorenzen N, Otzen D, McLean P, et al.
Proc Natl Acad Sci U S A
. 2016 Jul;
113(32):E4708-15.
PMID: 27457957
Emerging evidence strongly suggests that chaperone proteins are cytoprotective in neurodegenerative proteinopathies involving protein aggregation; for example, in the accumulation of aggregated α-synuclein into the Lewy bodies present in Parkinson's...
20.
Paslawski W, Lorenzen N, Otzen D
Methods Mol Biol
. 2015 Oct;
1345:133-50.
PMID: 26453210
The aggregation of α-synuclein (αSN) into oligomeric structures has received increasing interest during the last 10-15 years. The oligomers' potential involvement in Parkinson's disease makes them a promising therapeutic target....